Home▸GLP-1/GIP Weight Loss Drug Mechanism▸GLP-1 Muscle Mass Preservation Strategy Simulator

💉 GLP-1 Muscle Mass Preservation Strategy Simulator

This simulation explores the strategy of preserving muscle mass during GLP-1 therapy. It provides insights into how different dosages and treatment durations can impact muscle health in patients undergoing this type of medication.

GLP-1/GIP Weight Loss Drug Mechanism2DModerate60 FPS
glp1-muscle-mass-preservation-simulator ↗ Open standalone

Baseline Body Composition

Placeholder lead: fat and lean mass before any GLP-1 intervention starts.

  • ~30%: Typical fat mass (placeholder baseline share)
  • ~70%: Typical lean mass (placeholder baseline share)
  • Appetite ↓: GLP-1 mechanism (placeholder short note)
  • 6–12 mo: Weight loss horizon (placeholder timeline)

Why baseline composition matters

Placeholder section text: fat vs lean split sets the reference point for tracking losses.

GLP-1 Therapy and the Caloric Deficit

Placeholder lead: appetite suppression creates a deficit pulling from both tissue types.

  • Appetite ↓: Deficit source (placeholder mechanism note)
  • ~6%: Early total loss (placeholder body weight)
  • Fat + lean: Loss source (placeholder composition)
  • Early months: Risk window (placeholder timing)

Deficit draws from both compartments

Placeholder section text: rapid loss pulls energy from fat stores and lean tissue alike.

Unaddressed Muscle Loss Risk

Placeholder lead: lean mass can reach roughly 40 percent of total weight lost.

  • ~40%: Lean share (unmanaged) (placeholder of total loss)
  • ~60%: Fat share (unmanaged) (placeholder of total loss)
  • Strength ↓: Functional risk (placeholder consequence)
  • RMR ↓: Metabolic risk (placeholder consequence)

Why unmanaged loss skews lean

Placeholder section text: deficit alone does not protect muscle tissue from being metabolized.

Resistance Training + Protein Intervention

Placeholder lead: training and protein intake redirect loss toward fat stores.

  • 0–5 /wk: Training lever (placeholder session range)
  • 0.8–2.0 g/kg: Protein lever (placeholder intake range)
  • ~8%: Best-case lean share (placeholder of total loss)
  • Anabolic signal: Mechanism (placeholder short note)

Two levers that preserve lean tissue

Placeholder section text: mechanical loading plus amino acid supply protect muscle protein.

Outcome Comparison — Same Weight, Different Composition

Placeholder lead: identical total loss can mean very different fat-to-lean outcomes.

  • 13%: Total loss (both paths) (placeholder body weight)
  • ~40%: Unmanaged lean loss (placeholder of loss)
  • ~8–15%: Managed lean loss (placeholder of loss)
  • 0–100: Preservation score range (placeholder scale)

Composition, not just the scale, matters

Placeholder section text: two paths to the same weight loss diverge sharply in body composition.

Placeholder highlight: prioritizing lean mass preservation changes long-term outcomes.
⚙ Under the hood

This simulation explores the strategy of preserving muscle mass during GLP-1 therapy. It provides insights into how different dosages and treatment durations can impact muscle health in patients undergoing this type of medication.

CanvasBiomedicine

2D · HTML5 Canvas 2D · 60 FPS target · runs fully client-side, no install

What did you find?

Add reproduction steps (optional)